Prot #D933RC00001: A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed by Durvalumab Alone for Adjuvant Treatment i

Project: Research project

StatusActive
Effective start/end date11/20/1911/20/22

Funding

  • AstraZeneca Pharmaceuticals LP (Prot #D933RC00001)